PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology ...

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.

9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical ...

Google DeepMind's new model deciphers how hidden DNA changes drive disease, predicting gene regulation effects with high ...

Google DeepMind’s research team recently disclosed in the international academic journal *Nature* the development process of ...

Wave is expecting feedback from US regulators on a path forward for WVE-006 as a potential alpha-1 antitrypsin deficiency therapy in mid-2026.

Only approximately 2 per cent of the human genome encodes proteins, the rest being left to serve as an elaborate control system- one that harbors much of the variants associated with common disease.

In 2023, Krainer published a paper in which he showed SRSF1’s involvement in PDAC. The most common form of pancreatic cancer, PDAC is also the most life- threatening. By increasing SRSF1 into a system ...

The RNA analysis market is poised for significant growth due to rising demand in precision medicine, advancements in NGS technologies, and expanding use of RNA biomarkers in diagnostics and drug ...

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the ...